==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1662 details
Primary information
ThPP IDTh1154
Therapeutic Peptide/Protein NameOspA lipoprotein
SequenceMKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDG view full sequnce in fasta
Functional ClassificationIIIa
Molecular Weight27743.1
Chemical FormulaC1198H2012N322O422S2
Isoelectric Point6.72
Hydrophobicity-0.652
Melting Point (℃)N.A.
Half Life1.2 Hrs (Mammalian reticulocytes,in vitro)
DescriptionVaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.
Indication/DiseaseFor prophylactic treatment of Lyme Disease
PharmacodynamicsOspA lipoprotein is a single polypeptide chain of 270 amino acids. It is a vaccination used to prevent Lyme Disease.
Mechanism of ActionOspA lipoprotein, an outer surface protein of the bacteria Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. It is used as a vaccination against Lyme Disease, a disease carried by ticks.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesVaccines
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
Target Toll-like receptor 2
Information of corresponding available drug in the market
Brand NameLymerix
CompanySmithKline Beecham
Brand DiscriptionThe causative agent of Lyme disease is Borrelia burgdorferi; in North America, all Lyme disease is due to Borrelia burgdorferi sensu stricto. The vaccine contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. The vaccine is adsorbed onto aluminum hydroxide
Prescribed forYMErix (lipoprotein outer surface a vaccine) is indicated for active immunization against Lyme disease in individuals 15 to 70 years of age.
Chemical NameN.A.
FormulationEach 0.5 mL dose of vaccine consists of 30 mcg of lipoprotein OspA adsorbed onto 0.5 mg aluminum as aluminum hydroxide adjuvant. Each dose of the vaccine preparation contains 10 mM phosphate buffered saline and 2.5 mg of 2-phenoxyethanol, a bacteriostatic agent.
Physcial AppearnceLYMErix (lipoprotein outer surface a vaccine) is supplied as a sterile suspension
Route of AdministrationIntramuscular Injection
Recommended DosagePrimary immunization against Lyme disease consists of a 30 mcg/0.5 mL dose of LYMErix (lipoprotein outer surface a vaccine) given at 0, 1 and 12 months.
ContraindicationLYMErix (lipoprotein outer surface a vaccine) is contraindicated in people with known hypersensitivity to any component of the vaccine.
Side EffectsHyperntension, Diarrhea, Arthritis, Backpain, Depression, Sinusitis, Rashes, Headache, Dizziness, Depression, Fever, Fatigue.
Useful Linkhttp://www.rxlist.com/lymerix-drug.htm
PubMed ID9261945, 8418068
3-D StructureTh1154 (View) or (Download)